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Acid β-glucosidase deﬁciencyEliglustat is an investigational, oral substrate reduction therapy for Gaucher disease type 1 (GD1). Nineteen
treatment-naïve patients have now completed 4 years of an open-label study (NCT00358150). Mean hemo-
globin level and platelet count increased by 2.3 ± 1.5 g/dL (baseline: 11.3 ± 1.5 g/dL) and 95% (baseline:
68,700 ± 21,200/mm3), respectively. Mean spleen and liver volumes (multiples of normal, MN) decreased by
63% (baseline: 17.3 ± 9.5 MN) and 28% (baseline: 1.7 ± 0.4 MN), respectively. Median chitotriosidase
and CCL-18 each decreased by 82%; plasma glucosylceramide and GM3 normalized. Mean bone mineral density
T-score for the lumbar spine increased by 0.8 (60%) (baseline:−1.6 ± 1.1). Femur dark marrow, a reﬂection of
Gaucher cell inﬁltration into bone marrow, was reduced or stable in 17/18 patients. There were no bone crises.
Most adverse events were mild and unrelated to treatment. These results extend the safety and efﬁcacy of
eliglustat reported at 1 and 2 years to 4 years.
© 2014Genzyme, a Sanoﬁ company. Publishedby Elsevier B.V. This is an open access article under the CCBY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).Introduction
Eliglustat is an investigational oral substrate reduction therapy
for adults with Gaucher disease type 1 (GD1). This lysosomal storage
disorder is characterized by deﬁcient activity of the enzyme acid
β-glucosidase (glucocerebrosidase) resulting in pathogenic accumula-
tion of its substrate glucosylceramide (GL-1) in macrophages, leading
to hepatosplenomegaly, pancytopenia, skeletal disease, and chronic
bone pain [1].me replacement therapy; GD1,
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by Elsevier B.V. This is an open accessEliglustat is pharmacologically distinct from enzyme replacement
therapy (ERT), the current standard of care for GD1 [2,3]. ERT supplies
exogenous acid β-glucosidase to break down accumulated gluco-
sylceramide. Eliglustat, a ceramide analog, inhibits glucosylceramide
synthase, thereby reducing synthesis of its substrate, glucosylceramide,
to balance production with the impaired rate of degradation. The
efﬁcacy, safety, and tolerability of eliglustat after 1 and 2 years of treat-
ment were demonstrated in a Phase 2 trial of treatment-naïve adult
patients with GD1 [4,5]. Here, we report the long-term outcomes after
4 years of eliglustat treatment in this ongoing trial.Materials and methods
As previously described, this open-label, single-arm, multicenter
study (NCT00358150) sponsored by Genzyme, a Sanoﬁ company en-
rolled 26 adults with conﬁrmed acid β-glucosidase deﬁciency, spleno-
megaly (volume 10 × normal [normal = 0.2% body weight]), platelet
counts of 45,000/mm3 to 100,000/mm3, and/or hemoglobin levels of
8.0 g/dL to 10.0 g/dL [4]. Study participants provided written informedarticle under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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Fig. 2. Improvements in platelet counts after 4 years relative to baseline. Each point
represents one patient. Platelet count improved in all patients as noted by the fact that
all points are above the solid line extending from the zero point. There was no correlation
between baseline platelet count andwhether or not patients attained the therapeutic goal
for platelets (a count of 120,000/mm3 or higher for those with moderate thrombocytope-
nia at baseline and a doubling of platelet count for thosewith severe thrombocytopenia at
baseline) (r = 0.212, P= 0.3830).
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proved by each center's Ethics Committee or Institutional ReviewBoard.
Long-term efﬁcacy endpoints included changes in hemoglobin level,
platelet counts, spleen volume, and liver volume, as well as changes in
GD1-related biomarkers and bone assessments from baseline to
4 years. Hemoglobin level, platelet count, and plasma biomarkers
were analyzed at central laboratories. Spleen and liver volumes were
derived frommagnetic resonance imaging (MRI) or spiral computed to-
mography scans. Skeletal assessments were based on radiography,
dual energy x-ray absorptiometry, and MRI. Imaging results were
assessed by independent central reviewers. Safety assessments
through 4 years included adverse events and laboratory, electrocar-
diographic, physical, neurologic, and nerve conduction velocity
evaluations.
Results and discussion
Demographics and baseline characteristics of the study population
have been reported previously [4]. Nineteen of the 26 enrolled patients
completed the 4-year evaluation. Of these, 10 were female and 9 were
male; ages at baseline ranged from 18 to 56 years (mean 33.6 years).
Fifteen patients received eliglustat 100 mg twice daily, 3 patients re-
ceived 50 mg twice daily, and one patient received 50 mg twice daily
for 3 years then increased to 100 mg twice daily for the fourth year.
Improvements observed in spleen and liver volumes, hemoglobin
levels, and platelet counts during the ﬁrst and second years of eliglustat
treatment were maintained and extended through 4 years (Fig. 1),
demonstrating the long-term efﬁcacy of eliglustat. At 4 years, 100% of
patients met the therapeutic goals established for long-term ERT treat-
ment [6] for spleen volume and hemoglobin level, 94% met the goal for
liver volume, and 47% met the goal for platelet count.
Low platelet counts represent a central abnormality in GD1, yet rea-
sons for persistent thrombocytopenia (platelet counts b120,000/mm3
after 4 or 5 years of therapy) in some ERT-treated, nonsplenectomized
patients remain obscure [7]. Even after 5 or 10 years of ERT, platelet
countsmaynot normalize in somenonsplenectomized patientswith se-
vere baseline thrombocytopenia [8,9]. After 4 years of eliglustat treat-
ment, 17/19 patients attained platelet counts ≥80,000 (Fig. 2). Of the
eight patients (42%) with severe thrombocytopenia (≤60,000/mm3)
at baseline, four achieved the treatment goal of doubled platelet count
and also achieved near-normal platelet levels of 100,000/mm3; one ad-
ditional severely thrombocytopenic patient achieved a platelet count of
100,000/mm3, although the baseline value was not doubled. Although
the mean platelet counts at 4 years did not correlate signiﬁcantly with-100%
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Fig. 1. Improvements in hematologic and organ volume parameters through 4 years
of eliglustat treatment. Data are reported as percent change from baseline for platelets,
liver and spleen, and change from baseline for hemoglobin in g/dL. All values are
means shownwith 95% conﬁdence intervals. P b 0.0001 for spleen, liver, and hemoglobin;
P = 0.0003 for platelets at 4 years. Clinically meaningful and statistically signiﬁcant
improvements were observed after 13 weeks of treatment for hemoglobin levels
(P b 0.05) [4], and after 6 months for platelet counts (P b 0.01) and spleen and
liver volumes (P b 0.0001 for both) [4].the extent of thrombocytopenia (Fig. 2), splenomegaly, or splenic ﬁlling
defects at baseline, they did correlate with the mean eliglustat trough
plasma concentrations (r= 0.731, P= 0.0004).
After 4 years of eliglustat treatment, improvements in disease bio-
markers were sustained, with signiﬁcant reductions in chitotriosidase
and CCL18, and normalization of the exploratory biomarkers of
glucosylceramide synthase inhibition, GL-1 and GM3. Median
chitotriosidase (n = 17) and CCL18 (n = 18) levels each decreased by
82% (P b 0.0001) from baseline to 4 years: chitotriosidase from 8084
to 1394 nmol/h/mL (normal range: b15 to 181 nmol/h/mL) and
CCL18 from3560 to 475.5 ng/mL (normal range: 17 to 246 ng/mL).Me-
dian plasmaGL-1 decreased by 80% (P b 0.001) from 12.15 to 2.0 μg/mL
(normal range: b2.0 to 6.6 μg/mL) and GM3 decreased by 74% from
19.4 to 5.9 μg/mL (normal range: 5.0 to 9.2 μg/mL).
Bone pathology represents a primary and often progressive clinical
feature of GD1, perhaps caused by a disruption of the normal bone re-
modeling process [10,11]. Long-term eliglustat treatment maintained
improvements in both osseous and marrow bone compartments.
Fifteen of 19 patients had evaluable bone data over the 4‐year period,
12 of whomhad osteopenia or osteoporosis of the lumbar spine at base-
line. With eliglustat treatment, the mean bone mineral density (BMD)
T-score for the lumbar spine increased signiﬁcantly (P= 0.014) by 0.8
(9.9% in BMD g/cm2) from baseline to 4 years, an improvement that
moved the mean T-score out of the osteopenia range (−1.0 to−2.5)
and into the normal range (−1.0 to 1.0) (Fig. 3). Femur MRI results
showed stabilized or improved bonedisease over 4 years. Darkmarrow,
which was present in 18 of 19 (95%) patients at baseline, improved in 9
patients (50%), was stable in 8 patients (44%), and was possibly en-
larged in 1 patient (6%) at 4 years [12]. Lytic lesions present in 8 of 19
(42%) patients at baseline remained stable and no new lesions were
identiﬁed. No bone crises were reported for the duration of the trial.
Safety outcomes for the ﬁrst 2 years of eliglustat treatment have
been published [4,5]. No substantial new safety issues have arisen
since then. After 4 years, a total of 191 treatment-emergent adverse
events were reported in 23 patients, of which 74% were classiﬁed as
mild and 95% were assessed as unrelated to treatment. Ten related
treatment-emergent adverse events, all of which were mild, were re-
ported in eight patients; each related adverse event occurred in one or
two patients. All three patients who had peripheral nerve treatment
emergent adverse events considered related to treatment were asymp-
tomatic and had discordant neurological exam and nerve conduction
ﬁndings; all have continued eliglustat treatment [5]. Most related
treatment-emergent adverse events (7/10) occurred during the ﬁrst
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Fig. 3.Mean lumbar spine bone mineral density improvement from osteopenia to normal range after 4 years of eliglustat treatment. Values for the lumbar spine represent the mean
changes in T-score from baseline and the signiﬁcance of the changes at each time. One patient was excluded after starting treatment with bisphosphonates (after Year 1).
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verse events were reported in three patients, all during the ﬁrst year of
treatment and as previously reported. No deaths occurred. In 4 years,
there were seven discontinuations; four in the ﬁrst year (two due to
pregnancy and two due to asymptomatic nonsustained ventricular
tachycardia after one dose) [4,5], two during the second year (pregnancy
and bone lesion) [4,5], and one during the third year (administrative).
Conclusion
Long-term follow-upof eliglustat treatment for previously untreated
GD1 patients demonstrated continuation and maintenance of improve-
ments in hematologic parameters, organ volumes, disease-related bio-
markers, and bone parameters. Phase 3 clinical trials in progress will
further elucidate the efﬁcacy and safety of eliglustat in a larger popula-
tion of treatment-naïve GD1 patients as well as in GD1 patients previ-
ously stabilized on enzyme replacement therapy.
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